Tislelizumab Bests Docetaxel in NSCLC Tislelizumab Bests Docetaxel in NSCLC
The new immunotherapy prolonged overall survival when compared with docetaxel in patients with locally advanced non-small cell lung cancer (NSCLC).Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 22, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Combo Disappoints in Metastatic Prostate Cancer Combo Disappoints in Metastatic Prostate Cancer
Combining the tyrosine kinase inhibitor saracatinib with docetaxel does not benefit patients with metastatic, castration-resistant prostate cancer, according to researchers.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 12, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Janssen Announces Treatment with ERLEADA ® (apalutamide) Significantly Improved Overall Survival in Patients with Metastatic Castration-Sensitive Prostate Cancer
RARITAN, N.J., February 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the final analysis of the Phase 3 TITAN study, which demonstrated the continued statistically significant benefit of the addition of ERLEADA® (apalutamide) to androgen deprivation therapy (ADT) in overall survival (OS) in patients with metastatic castration-sensitive prostate cancer (mCSPC), regardless of extent of disease, when compared to placebo plus ADT.[1] Results will be featured in an oral presentation at the American Society of Clinical Oncology’s Genitourinary (ASCO GU) Cancers Symposiu...
Source: Johnson and Johnson - February 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen to Highlight Robust Solid Tumor Portfolio and Pipeline at 2021 ASCO GU
February 2, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it will highlight the depth of its solid tumor portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium with 12 data presentations, including three company-sponsored oral presentations from the ERLEADA® (apalutamide) clinical development program. The virtual meeting will take place February 11-13, 2021. “We are committed to the development of innovative therapies for patients with genitourinary cancers for whom there remains a high unmet need,” said Craig Tendler, M...
Source: Johnson and Johnson - February 2, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Higher Intensity Therapy and Surgical Risk in Esophageal Cancer Higher Intensity Therapy and Surgical Risk in Esophageal Cancer
Combining standard neoadjuvant chemotherapy for locally advanced esophageal cancer with either radiation or docetaxel did not increase the risk of surgical complications, investigators in the JCOG1109 trial reported.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 29, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Comunicado de la FDA sobre la seguridad de los medicamentos: FDA advierte que el medicamento para el c áncer docetaxel puede causar síntomas de intoxicación alcohólica después del tratamiento
[6-20-2014] La Administraci ón de Alimentos y Medicamentos de Estados Unidos (FDA por sigla en inglés) advirtió que el medicamento docetaxel para la quimioterapia intravenosa contiene etanol, también conocido como alcohol, que puede hacer que los pacientes se sientan intoxicados o ebrios durante y después del tratamiento. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 19, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Better Survival With S-1/Docetaxel in Stage III Gastric Cancer Better Survival With S-1/Docetaxel in Stage III Gastric Cancer
Postoperative adjuvant S-1/docetaxel after D2 gastrectomy significantly improved survival in comparison with S-1 alone for patients with stage III gastric cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 18, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
European Commission approves Roche ’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for people with HER2-positive breast cancer
Basel, 23 December 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Phesgo®, a fixed-dose combination of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subcutaneous (SC; under the skin) injection for the treatment of early and metastatic HER2-positive breast cancer.“This approval represents a significant step forward in the treatment of HER2-positive breast cancer,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “The innovation of Phesgo significantly reduces the ti...
Source: Roche Media News - December 23, 2020 Category: Pharmaceuticals Source Type: news
European Commission approves Roche ’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for people with HER2-positive breast cancer
Basel, 23 December 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Phesgo®, a fixed-dose combination of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subcutaneous (SC; under the skin) injection for the treatment of early and metastatic HER2-positive breast cancer.“This approval represents a significant step forward in the treatment of HER2-positive breast cancer,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “The innovation of Phesgo significantly reduces the ti...
Source: Roche Investor Update - December 23, 2020 Category: Pharmaceuticals Source Type: news
Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020
Basel, 17 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that results from a number of studies across its broad oncology portfolio will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which will be held 19-21 September, 2020. Results include data from three phase III studies across the Tecentriq® (atezolizumab) triple-negative breast cancer (TNBC) programme. Central nervous system (CNS) efficacy data from integrated analyses of the pivotal phase II Rozlytrek® STARTRK-2, phase I STARTRK-1, and phase I ALKA-372-001 trials will be presented in addition to results ...
Source: Roche Media News - September 17, 2020 Category: Pharmaceuticals Source Type: news
Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020
Basel, 17 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that results from a number of studies across its broad oncology portfolio will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which will be held 19-21 September, 2020. Results include data from three phase III studies across the Tecentriq® (atezolizumab) triple-negative breast cancer (TNBC) programme. Central nervous system (CNS) efficacy data from integrated analyses of the pivotal phase II Rozlytrek® STARTRK-2, phase I STARTRK-1, and phase I ALKA-372-001 trials will be presented in addition to results ...
Source: Roche Investor Update - September 17, 2020 Category: Pharmaceuticals Source Type: news
Does Obesity Reduce Drug Efficacy in Breast Cancer? Does Obesity Reduce Drug Efficacy in Breast Cancer?
Poor survival outcomes occurred among overweight patients treated with docetaxel-based adjuvant chemotherapy compared with peers given a non-taxane-based regimen.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 10, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Popular chemotherapy drug may be less effective in overweight and obese women
(KU Leuven) Breast cancer patients who are overweight or obese might benefit less from treatment with docetaxel, a common chemotherapy drug, than lean patients, a new study finds. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 2, 2020 Category: International Medicine & Public Health Source Type: news
FDA approves Roche ’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for HER2-positive breast cancer
Basel, 29 June 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Phesgo ™, a fixed-dose combination of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subcutaneous (SC; under the skin) injection in combination with intravenous (IV) chemotherapy, for the treatment of early and metastatic HER2-positive breast cancer. This is the first time that Roche has combined two monoclonal antibodies that can be administered by a single SC injection.“The FDA approval of Phesgo reflects our commitment...
Source: Roche Media News - June 29, 2020 Category: Pharmaceuticals Source Type: news
